Sunwin Stevia International, Inc. (SUWN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sunwin Stevia International, Inc. (SUWN). Sunwin Stevia International, Inc. produces and sells natural sweeteners and pharmaceutical products in China. Market cap: 0, Sector: Consumer defensive.
Last analyzed: Mar 17, 2026Sunwin Stevia International, Inc. (SUWN) Consumer Business Overview
Sunwin Stevia International, Inc. is a Chinese agricultural farm products company focused on producing and selling natural sweeteners and pharmaceutical products. The company's core products include steviol glycosides and Metformin, targeting the food and pharmaceutical industries within China's consumer defensive sector. It faces challenges typical of OTC-listed companies.
Investment Thesis
Investing in Sunwin Stevia International, Inc. presents a high-risk, high-reward scenario. The company's focus on natural sweeteners and diabetes medication aligns with growing health trends, but its financial performance and OTC listing raise concerns. With a negative profit margin of -11.5% and trading on the OTC market, SUWN's viability hinges on improving profitability and transparency. Potential catalysts include expanding its market reach within China and developing new stevia-based products. However, investors must consider the risks associated with OTC-listed companies, including limited liquidity and regulatory oversight. The company's small market capitalization and negative P/E ratio highlight its speculative nature. Success depends on effective management of operational costs and successful commercialization of its product lines. The company's beta of 0.02 suggests low volatility, but this may be misleading due to the limited trading volume on the OTC market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited resources and higher risk.
- Negative P/E ratio of -0.00 reflects the company's current unprofitability.
- Profit margin of -11.5% suggests operational inefficiencies or pricing pressures.
- Gross margin of 8.8% indicates a narrow margin for covering operating expenses.
- Beta of 0.02 suggests low volatility relative to the market, but this may be due to limited trading volume.
Competitors & Peers
Strengths
- Focus on natural sweeteners aligns with health trends.
- Production of Metformin provides a diversified revenue stream.
- Established presence in the Chinese market.
- Proprietary Stevia Extraction Process (potential)
Weaknesses
- Negative profit margin indicates financial instability.
- OTC listing raises concerns about transparency and liquidity.
- Small market capitalization limits access to capital.
- Reliance on the Chinese market exposes it to regional risks.
Catalysts
- Upcoming: Potential partnerships with food and beverage companies to integrate Sunwin Stevia's sweeteners into new products.
- Ongoing: Increasing consumer demand for natural sweeteners as a healthier alternative to sugar.
- Ongoing: Expansion of the diabetes medication market in China due to rising prevalence of the disease.
Risks
- Potential: Regulatory changes in the food and drug industries could impact Sunwin Stevia's operations and product approvals.
- Potential: Fluctuations in raw material prices (stevia) could affect the company's profitability.
- Ongoing: Competition from established sweetener and pharmaceutical companies with greater resources.
- Ongoing: Limited liquidity and transparency due to OTC listing.
Growth Opportunities
- Expansion within the Chinese Market: Sunwin Stevia can capitalize on the growing demand for natural sweeteners and diabetes treatments within China. The Chinese market represents a significant opportunity due to its large population and increasing health consciousness. By strengthening its distribution network and marketing efforts, Sunwin Stevia can increase its market share and revenue. This expansion could be realized within the next 2-3 years, potentially doubling its sales volume if it captures even a small percentage of the market.
- New Product Development: Sunwin Stevia can invest in research and development to create new stevia-based products and formulations. This includes developing innovative sweeteners for specific applications in the food and beverage industry, as well as exploring new pharmaceutical applications for stevia. Successful product development can lead to increased revenue streams and a stronger competitive position. This initiative could yield results within 3-5 years, with new products contributing significantly to revenue growth.
- Strategic Partnerships: Forming strategic partnerships with food and beverage manufacturers, pharmaceutical companies, and ingredient distributors can provide Sunwin Stevia with access to new markets and distribution channels. These partnerships can accelerate its growth and reduce its reliance on direct sales. Collaborations with established players in the industry can enhance its credibility and market reach. These partnerships could be established within the next year, leading to immediate gains in market access and sales.
- Export Opportunities: Sunwin Stevia can explore export opportunities to expand its reach beyond China. The global demand for natural sweeteners is growing, and Sunwin Stevia can target markets in Asia, Europe, and North America. Exporting its products can diversify its revenue streams and reduce its dependence on the Chinese market. This expansion could be initiated within the next 2 years, with exports contributing a significant portion of its revenue within 5 years.
- Vertical Integration: Sunwin Stevia can pursue vertical integration by acquiring or developing its own stevia farms and processing facilities. This can reduce its reliance on external suppliers and improve its control over the supply chain. Vertical integration can lead to cost savings and improved product quality. This initiative could be implemented over the next 3-5 years, resulting in significant cost efficiencies and improved profitability.
Opportunities
- Expansion within the Chinese market.
- New product development in stevia-based sweeteners.
- Strategic partnerships with food and beverage manufacturers.
- Export opportunities to global markets.
Threats
- Competition from established sweetener and pharmaceutical companies.
- Regulatory changes in the food and drug industries.
- Fluctuations in raw material prices (stevia).
- Economic downturns in China.
Competitive Advantages
- Proprietary Stevia Extraction Process: Sunwin Stevia may have developed unique methods for extracting and purifying stevia, giving them a cost or quality advantage.
- Established Relationships in China: Long-standing relationships with distributors and manufacturers in China can create barriers to entry for new competitors.
- Brand Recognition (OnlySweet): If OnlySweet has gained consumer recognition, it can provide a competitive edge.
- Metformin Production: Manufacturing and selling Metformin provides a diversified revenue stream and access to the pharmaceutical market.
About SUWN
Sunwin Stevia International, Inc., based in Qufu, China, specializes in the production and sale of natural sweeteners and pharmaceutical products, primarily within the People's Republic of China. The company operates through two segments: Stevioside, focusing on natural sweeteners, and Corporate and Other Pharmaceutical, dealing with pharmaceutical products like Metformin. Founded to capitalize on the growing demand for natural sweeteners and diabetes treatments, Sunwin Stevia has evolved to offer a range of steviol glycosides, including rebaudioside A and stevioside, which serve as the principal components in its sweetener products. The company's product portfolio includes Steviosin, a low-calorie stevia extract targeted for medicinal applications, and OnlySweet, a zero-calorie tabletop sweetener aimed at food and drug manufacturers, as well as ingredient distributor foreign trade companies. These products are designed to cater to the increasing consumer preference for healthier, natural alternatives to traditional sweeteners. Additionally, Sunwin Stevia produces and sells Metformin, a widely prescribed medication for the treatment of type 2 diabetes, addressing a significant health concern in China and globally. Sunwin Stevia's market position is primarily within China, where it competes with other sweetener and pharmaceutical manufacturers. Its focus on natural sweeteners aligns with global health trends, but its reliance on the Chinese market exposes it to specific regional economic and regulatory factors. The company's strategy involves leveraging its stevia production capabilities and pharmaceutical offerings to serve both the food industry and the healthcare sector.
What They Do
- Produces and sells steviol glycosides, including rebaudioside A and stevioside.
- Offers Steviosin, a low-calorie stevia extract for medicinal use.
- Provides OnlySweet, a zero-calorie tabletop sweetener for food and drug manufacturers.
- Produces and sells Metformin, a medication for the treatment of type 2 diabetes.
- Targets food and drug manufacturers with natural sweetener products.
- Supplies ingredient distributor foreign trade companies.
Business Model
- Production and sale of stevia-based sweeteners.
- Manufacturing and distribution of Metformin for diabetes treatment.
- Sales to food and drug manufacturers.
- Distribution through foreign trade companies.
Industry Context
Sunwin Stevia International, Inc. operates within the agricultural farm products industry, specifically focusing on natural sweeteners and pharmaceutical products. The global natural sweetener market is experiencing growth due to increasing consumer awareness of health and wellness, with stevia being a prominent alternative to traditional sugars. The pharmaceutical segment, particularly diabetes medication, is also expanding due to the rising prevalence of diabetes worldwide. However, the industry is competitive, with established players and evolving regulatory landscapes. Sunwin Stevia's position within this market is primarily focused on the Chinese market, where it competes with both domestic and international companies.
Key Customers
- Food manufacturers seeking natural sweeteners.
- Drug manufacturers requiring stevia extracts.
- Ingredient distributor foreign trade companies.
- Patients with type 2 diabetes (for Metformin).
Financials
Chart & Info
Sunwin Stevia International, Inc. (SUWN) stock price: Price data unavailable
Latest News
No recent news available for SUWN.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SUWN.
Price Targets
Wall Street price target analysis for SUWN.
MoonshotScore
What does this score mean?
The MoonshotScore rates SUWN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Agricultural Farm ProductsLeadership: Chunchun Wang
CEO
Chunchun Wang serves as the CEO of Sunwin Stevia International, Inc. He is responsible for managing the company's overall operations and strategic direction. Wang's background includes experience in the agricultural and pharmaceutical sectors, with a focus on the production and sale of natural sweeteners and diabetes medications. His leadership is crucial in navigating the competitive landscape and driving the company's growth in the Chinese market.
Track Record: Under Chunchun Wang's leadership, Sunwin Stevia International, Inc. has focused on expanding its product portfolio and strengthening its presence in the Chinese market. Key milestones include the development of new stevia-based products and the continued production of Metformin. However, the company's financial performance remains a challenge, with negative profit margins and reliance on the OTC market.
SUWN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sunwin Stevia International, Inc. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Listing on the OTC Other tier is typically associated with speculative investments and requires careful due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC Other listing.
- Lack of regular financial reporting and transparency.
- Higher price volatility compared to exchange-listed stocks.
- Potential for delisting or trading suspension.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with regulatory requirements.
- Monitor trading volume and price activity for unusual patterns.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with OTC investments.
- Production and sale of tangible products (stevia sweeteners and Metformin).
- Operational presence in China.
- CEO and management team in place.
- Focus on a growing market (natural sweeteners and diabetes treatment).
Sunwin Stevia International, Inc. Stock: Key Questions Answered
What does Sunwin Stevia International, Inc. do?
Sunwin Stevia International, Inc. is engaged in the production and sale of natural sweeteners and pharmaceutical products, primarily in China. The company focuses on steviol glycosides, including rebaudioside A and stevioside, which are used as zero-calorie sweeteners in the food and beverage industry. Additionally, Sunwin Stevia produces and sells Metformin, a medication for the treatment of type 2 diabetes. The company targets food and drug manufacturers, as well as ingredient distributors, with its sweetener products, and serves the healthcare sector with its pharmaceutical offerings. Its business model centers on leveraging its stevia production capabilities and pharmaceutical expertise to cater to both the food and healthcare markets in China.
What are the main risks for SUWN?
Sunwin Stevia International, Inc. faces several risks, including its OTC listing, which results in limited liquidity and transparency. The company's financial performance, characterized by negative profit margins, raises concerns about its long-term viability. Competition from larger, more established companies in the sweetener and pharmaceutical industries poses a threat to its market share. Regulatory changes in the food and drug sectors could also impact its operations and product approvals. Additionally, fluctuations in raw material prices, particularly stevia, could affect its profitability. The company's reliance on the Chinese market exposes it to regional economic and regulatory risks.
How does Sunwin Stevia International, Inc. manage supply chain and input cost risks?
Given that Sunwin Stevia International, Inc. operates in the agricultural farm products sector, managing supply chain and input cost risks is crucial. The company's primary raw material is stevia, and fluctuations in its price can significantly impact profitability. To mitigate these risks, Sunwin Stevia may employ strategies such as securing long-term supply contracts with stevia farmers, diversifying its sourcing to multiple regions, and investing in research and development to improve stevia yields and extraction efficiency. Vertical integration, by acquiring or developing its own stevia farms, could also provide greater control over the supply chain and reduce reliance on external suppliers. Furthermore, hedging strategies and cost-control measures can help manage input cost volatility.
What are the key factors to evaluate for SUWN?
Evaluating SUWN involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Focus on natural sweeteners aligns with health trends.. Primary risk to monitor: Potential: Regulatory changes in the food and drug industries could impact Sunwin Stevia's operations and product approvals.. This is not financial advice.
How frequently does SUWN data refresh on this page?
SUWN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SUWN's recent stock price performance?
Recent price movement in Sunwin Stevia International, Inc. (SUWN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on natural sweeteners aligns with health trends.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SUWN overvalued or undervalued right now?
Determining whether Sunwin Stevia International, Inc. (SUWN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SUWN?
Before investing in Sunwin Stevia International, Inc. (SUWN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and disclosure status.
- AI analysis is pending, which may provide additional insights.